<font color="red">Safety_3</font> <font color="red">,_3</font> <font color="red">tolerability_3</font> <font color="red">,_3</font> <font color="red">and_3</font> <font color="red">immunogenicity_3</font> after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age . 
<br>
<br> BACKGROUND <font color="red">Incidence_1</font> <font color="red">and_1</font> <font color="red">severity_1</font> of herpes zoster ( HZ ) and postherpetic neuralgia increase with age , associated with age - related decrease in immunity to varicella - zoster virus ( VZV ) . One dose of zoster vaccine ( ZV ) has demonstrated <font color="red">substantial_1</font> <font color="red">protection_1</font> <font color="red">against_1</font> <font color="red">HZ_1</font> <font color="red">;_1</font> this study examined <font color="red">impact_2</font> <font color="red">of_1</font> <font color="red">a_1</font> <font color="red">second_1</font> <font color="red">dose_1</font> <font color="red">of_1</font> <font color="red">ZV_1</font> <font color="red">._1</font> 
<br> METHODS Randomized , double - blind , multicenter study with 210 subjects ≥60 years old <font color="red">compared_1</font> <font color="red">immunity_2</font> <font color="red">and_2</font> <font color="red">safety_2</font> <font color="red">profiles_2</font> <font color="red">after_1</font> <font color="red">one_1</font> <font color="red">and_1</font> <font color="red">two_1</font> <font color="red">doses_1</font> <font color="red">of_1</font> <font color="red">ZV_1</font> <font color="red">,_1</font> separated by 6 weeks , vs. placebo . <font color="red">Immunogenicity_3</font> <font color="red">was_2</font> <font color="red">evaluated_2</font> <font color="red">using_1</font> <font color="red">VZV_2</font> <font color="red">interferon_2</font> <font color="red">-_2</font> <font color="red">gamma_2</font> <font color="red">(_2</font> <font color="red">IFN-γ_2</font> <font color="red">)_2</font> <font color="red">enzyme_2</font> <font color="red">-_2</font> <font color="red">linked_2</font> <font color="red">immunospot_2</font> <font color="red">(_2</font> <font color="red">ELISPOT_2</font> <font color="red">)_2</font> <font color="red">assay_2</font> <font color="red">and_1</font> <font color="red">VZV_2</font> <font color="red">glycoprotein_2</font> <font color="red">enzyme_2</font> <font color="red">-_2</font> <font color="red">linked_2</font> <font color="red">immunosorbent_2</font> <font color="red">antibody_2</font> <font color="red">(_2</font> <font color="red">gpELISA_2</font> <font color="red">)_2</font> <font color="red">assay_2</font> <font color="red">._2</font> <font color="red">Adverse_1</font> <font color="red">experiences_1</font> <font color="red">(_1</font> <font color="red">AEs_1</font> <font color="red">)_1</font> were recorded on a standardized <font color="red">Vaccination_1</font> <font color="red">Report_1</font> <font color="red">Card_1</font> <font color="red">._1</font> <font color="red">
<br>_1</font> <font color="red">RESULTS_1</font> <font color="red">No_1</font> <font color="red">serious_1</font> <font color="red">vaccine_2</font> <font color="red">-_2</font> <font color="red">related_2</font> <font color="red">AEs_2</font> <font color="red">occurred_1</font> <font color="red">._1</font> <font color="red">VZV_3</font> <font color="red">IFN-γ_3</font> <font color="red">ELISPOT_3</font> <font color="red">geometric_3</font> <font color="red">mean_3</font> <font color="red">count_3</font> <font color="red">(_3</font> <font color="red">GMC_3</font> <font color="red">)_3</font> <font color="red">of_2</font> <font color="red">spot_3</font> <font color="red">-_3</font> <font color="red">forming_3</font> <font color="red">cells_3</font> <font color="red">per_3</font> <font color="red">10(6_3</font> <font color="red">)_3</font> <font color="red">peripheral_3</font> <font color="red">blood_3</font> <font color="red">mononuclear_3</font> <font color="red">cells_3</font> <font color="red">increased_1</font> in the ZV group from 16.9 prevaccination to 49.5 and 32.8 at 2 and 6 weeks postdose 1 , respectively . Two weeks , 6 weeks and 6 months postdose 2 , <font color="red">GMC_2</font> was 44.3 , 42.9 , and 36.5 , respectively . <font color="red">GMC_2</font> in the placebo group did not change during the study . The <font color="red">peak_2</font> <font color="red">ELISPOT_2</font> <font color="red">response_2</font> occurred ∼2 weeks after each ZV dose . The <font color="red">gpELISA_2</font> <font color="red">geometric_2</font> <font color="red">mean_2</font> <font color="red">titers_2</font> <font color="red">(_2</font> <font color="red">GMTs_2</font> <font color="red">)_2</font> in the ZV group were <font color="red">higher_1</font> than in the placebo group at 6 weeks after each dose . <font color="red">Correlation_2</font> <font color="red">between_1</font> <font color="red">the_1</font> <font color="red">IFN-γ_2</font> <font color="red">ELISPOT_2</font> <font color="red">and_2</font> <font color="red">gpELISA_2</font> <font color="red">assays_2</font> <font color="red">was_1</font> <font color="red">poor_1</font> <font color="red">._1</font> 
<br> CONCLUSIONS <font color="red">ZV_1</font> was generally <font color="red">well_2</font> <font color="red">-_2</font> <font color="red">tolerated_2</font> <font color="red">and_2</font> <font color="red">immunogenic_2</font> in adults ≥60 years old . <font color="red">A_1</font> <font color="red">second_1</font> <font color="red">dose_1</font> <font color="red">of_1</font> <font color="red">ZV_1</font> <font color="red">was_1</font> <font color="red">generally_2</font> <font color="red">safe_2</font> <font color="red">,_2</font> <font color="red">but_1</font> <font color="red">did_1</font> <font color="red">not_1</font> <font color="red">boost_2</font> <font color="red">VZV_2</font> <font color="red">-_2</font> <font color="red">specific_2</font> <font color="red">immunity_2</font> <font color="red">beyond_1</font> <font color="red">levels_1</font> <font color="red">achieved_1</font> <font color="red">postdose_1</font> <font color="red">1_1</font> <font color="red">._1</font>